File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The potential clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma

TitleThe potential clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma
Authors
Issue Date2008
PublisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/surg
Citation
Surgery, 2008, v. 144 n. 6, p. 934-941 How to Cite?
AbstractBackground: Vascular endothelial growth factor (VEGF) promotes tumor angioinvasion while VEGF-C is a potent lymphangiogenic factor. This study aims at evaluating serum VEGF (sVEGF) and sVEGF-C levels in recurrent papillary thyroid carcinoma (PTC) patients. Methods: Serum samples were collected preoperatively from 85 patients with primary PTC, 44 with benign thyroid diseases, and 19 with recurrent PTC. sVEGF and sVEGF-C levels were measured by enzyme-linked immunosorbent assay. Results: Twelve patients had locoregional recurrence only while 7 patients had distant metastases, including 6 with concomitant or history of locoregional recurrence. Patients with recurrent PTC had significantly higher sVEGF (432 vs 263 pg/mL, P = .004) and sVEGF-C (6,433 vs 5,289 pg/mL, P = .006) levels than benign controls. sVEGF level was significantly elevated in patients with distant metastases compared with those of local recurrences only (580 vs 345 pg/mL, P = .037) while there was no significant difference of sVEGF-C level in both subgroup of patients. sVEGF, but not VEGF-C, showed a linear correlation with thyroglobulin levels in recurrent PTC patients. Conclusion: Both sVEGF and sVEGF-C levels are elevated in patients with recurrent PTC, and sVEGF distinguishes the presence of distant metastasis. Angiogenic markers should be further evaluated for their clinical relevance in monitoring and predicting the type of recurrence. © 2008 Mosby, Inc. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/59949
ISSN
2015 Impact Factor: 3.309
2015 SCImago Journal Rankings: 1.620
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYu, XMen_HK
dc.contributor.authorLo, CYen_HK
dc.contributor.authorLam, AKYen_HK
dc.contributor.authorLang, BHHen_HK
dc.contributor.authorLeung, Pen_HK
dc.contributor.authorLuk, JMen_HK
dc.date.accessioned2010-05-31T04:00:44Z-
dc.date.available2010-05-31T04:00:44Z-
dc.date.issued2008en_HK
dc.identifier.citationSurgery, 2008, v. 144 n. 6, p. 934-941en_HK
dc.identifier.issn0039-6060en_HK
dc.identifier.urihttp://hdl.handle.net/10722/59949-
dc.description.abstractBackground: Vascular endothelial growth factor (VEGF) promotes tumor angioinvasion while VEGF-C is a potent lymphangiogenic factor. This study aims at evaluating serum VEGF (sVEGF) and sVEGF-C levels in recurrent papillary thyroid carcinoma (PTC) patients. Methods: Serum samples were collected preoperatively from 85 patients with primary PTC, 44 with benign thyroid diseases, and 19 with recurrent PTC. sVEGF and sVEGF-C levels were measured by enzyme-linked immunosorbent assay. Results: Twelve patients had locoregional recurrence only while 7 patients had distant metastases, including 6 with concomitant or history of locoregional recurrence. Patients with recurrent PTC had significantly higher sVEGF (432 vs 263 pg/mL, P = .004) and sVEGF-C (6,433 vs 5,289 pg/mL, P = .006) levels than benign controls. sVEGF level was significantly elevated in patients with distant metastases compared with those of local recurrences only (580 vs 345 pg/mL, P = .037) while there was no significant difference of sVEGF-C level in both subgroup of patients. sVEGF, but not VEGF-C, showed a linear correlation with thyroglobulin levels in recurrent PTC patients. Conclusion: Both sVEGF and sVEGF-C levels are elevated in patients with recurrent PTC, and sVEGF distinguishes the presence of distant metastasis. Angiogenic markers should be further evaluated for their clinical relevance in monitoring and predicting the type of recurrence. © 2008 Mosby, Inc. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/surgen_HK
dc.relation.ispartofSurgeryen_HK
dc.subject.meshAdenocarcinoma, Papillary - blooden_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAged, 80 and overen_HK
dc.subject.meshChilden_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshNeoplasm Metastasisen_HK
dc.subject.meshNeoplasm Recurrence, Local - blooden_HK
dc.subject.meshThyroid Neoplasms - blooden_HK
dc.subject.meshTumor Markers, Biological - blooden_HK
dc.subject.meshVascular Endothelial Growth Factor A - blooden_HK
dc.subject.meshVascular Endothelial Growth Factor C - blooden_HK
dc.subject.meshYoung Adulten_HK
dc.titleThe potential clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinomaen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0263-9319&volume=144&spage=934&epage=941&date=2008&atitle=The+potential+clinical+relevance+of+serum+vascular+endothelial+growth+factor+(VEGF)+and+VEGF-C+in+recurrent+papillary+thyroid+carcinoma.en_HK
dc.identifier.emailLuk, JM: jmluk@hkucc.hku.hken_HK
dc.identifier.authorityLuk, JM=rp00349en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.surg.2008.07.027en_HK
dc.identifier.pmid19041000-
dc.identifier.scopuseid_2-s2.0-56449093108en_HK
dc.identifier.hkuros147156en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-56449093108&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume144en_HK
dc.identifier.issue6en_HK
dc.identifier.spage934en_HK
dc.identifier.epage941en_HK
dc.identifier.isiWOS:000261581600025-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridYu, XM=9534691000en_HK
dc.identifier.scopusauthoridLo, CY=16417392800en_HK
dc.identifier.scopusauthoridLam, AKY=7403657165en_HK
dc.identifier.scopusauthoridLang, BHH=7201907327en_HK
dc.identifier.scopusauthoridLeung, P=7401749062en_HK
dc.identifier.scopusauthoridLuk, JM=7006777791en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats